Analysis Phaarmasia Limited (PHRMASI)
6/2/2024
Analysis of Phaarmasia Limited (PHRMASI)
Phaarmasia Limited has shown some fluctuations in its stock price over the past few days. The Relative Strength Index (RSI) values have been hovering around 45-52, indicating a neutral to slightly bearish sentiment in the market.The Moving Average Convergence Divergence (MACD) indicator has been negative, suggesting a potential bearish trend. The MACD histogram has been consistently negative, indicating a strong bearish momentum.
The Moving Average (MA) indicator has been above the stock price, which could signal a potential downtrend. The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) have all been above the current price, further supporting a bearish outlook.
Overall, based on the technical indicators, Phaarmasia Limited may be facing some downward pressure in the near term. Traders and investors should closely monitor the price action and key support levels for potential entry or exit points.
Main Statystic ðŸ§
The data provides a comprehensive overview of the financial and stock-related metrics for a specific company. Here are the key points:1. **Financials**:
- **Cash Flow**: Operating cash flow for the trailing twelve months (TTM) is $110,563,000,320. Levered free cash flow TTM is $84,726,874,112.
- **Balance Sheet**: Total cash on a quarterly basis is $67,150,000,128. Total debt on a quarterly basis is $104,590,000,128. Current ratio is 1.037. Book value per share is $4.837. Total cash per share is $4.379. Total debt to equity ratio is 140.968.
- **Profit Margin**: The profit margin is 26.306%.
- **Income Statement**: EBITDA is $131,393,000,000. Revenue TTM is $381,623,009,280. Diluted EPS TTM is $6.43. Gross profit TTM is $169,148,000,000. Net income to common TTM is $100,389,003,264. Quarterly revenue growth is -4.3%. Quarterly earnings growth year-over-year is -2.2%.
- **Operating Margin**: The operating margin is 30.743%.
- **Return on Assets**: Return on assets TTM is 22.073999%.
- **Return on Equity**: Return on equity TTM is 147.25%.
2. **Stock Statistics**:
- Short ratio is 1.53. Float shares are 15,308,320,742. Shares short are 99,287,450. Average 10-day volume is 46,860,048. Average 90-day volume is 57,498,254. Shares outstanding are 15,334,099,968. Percentage held by insiders is 5.22%. Percentage held by institutions is 57.589%. Short percent of shares outstanding is 0.65%.
3. **Valuations Metrics**:
- PEG ratio is 26.319502. Forward PE ratio is 26.319502. Trailing PE ratio is 29.59409. Enterprise value is $2,950,762,332,160. Price to book ratio on a quarterly basis is 39.3405. Price to sales TTM is 7.646095. Enterprise to EBITDA ratio is 22.763. Enterprise to revenue ratio is 7.732. Market capitalization is $2,917,925,650,432.
4. **Stock Price Summary**:
- Beta is 1.264. 50-day moving average is $176.2646. 200-day moving average is $181.0429. 52-week low is $164.08. 52-week high is $199.62. 52-week change is 6.853%.
5. **Dividends and Splits**:
- Payout ratio is 14.93%. Dividend date is May 16, 2024. Last split date is August 31, 2020. Ex-dividend date is May 10, 2024. Last split factor is a 4-for-1 split. Forward annual dividend rate is $1. 5-year average dividend yield is 0.73%. Forward annual dividend yield is 0.5255%. Trailing annual dividend rate is $0.97. Trailing annual dividend yield is 0.5097%.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe the following trends:
1. There was a significant increase in revenue from 2020 to 2021, indicating strong growth.
2. The revenue continued to grow in 2022, reaching the highest point in the given period.
3. In 2023, there was a slight decrease in revenue compared to the previous year, but it still remained higher than the 2021 figures.
Overall, the company has shown a positive revenue trend over the past four years, with substantial growth and consistent performance.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $290,437,000,000 in 2023.
5. Shareholders' equity has shown variations but has generally increased, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, long-term debt issuance, and payments, with significant fluctuations in values.
6. Investing activities indicate a mix of acquisitions, investments, and capital expenditures, with varying levels of cash flow.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.
Revenue estimate
The analysts' estimates for the future quarterly and annual sales of the company indicate a moderate growth trend.For the current quarter ending on June 30, 2024, the average estimate is $77,545,400,000, with a sales growth of 2% compared to the same period last year. The number of analysts providing estimates is 25.
Looking ahead to the next quarter ending on September 30, 2024, the average estimate increases to $85,501,800,000, with a sales growth of 3% compared to the previous year. The number of analysts remains at 25.
For the current fiscal year ending on September 30, 2024, the average estimate for total sales is $357,772,000,000, showing a 1% growth compared to the previous fiscal year. The number of analysts providing estimates increases to 38.
In the following fiscal year ending on September 30, 2025, the average sales estimate further increases to $380,772,000,000, indicating a 6% growth compared to the current fiscal year. The number of analysts remains at 38.
Overall, the estimates suggest a steady growth trajectory for the company's sales in the upcoming quarters and years, with a slightly more optimistic outlook for the next fiscal year.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slight slowdown compared to the past 5 years but still showing healthy growth rates for the upcoming periods.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range of predictions, from a low of $164 to a high of $275, indicating some uncertainty in the market.
MACD of PHRMASI
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
